INVO Bioscience is soliciting waivers from holders of the company’s common stock purchase warrants dated August 8, of the holder’s right to exercise a cash payment option upon consummation of the previously announced proposed merger with NAYA Biosciences, a Delaware corporation. Receipt of the waivers is a condition to the consummation of the merger. The waiver solicitation is being made pursuant to a notice of waiver solicitation and accompanying form of waiver, which the company is sending to the holders of the warrants. The Notice of waiver solicitation sets forth the terms of the warrant solicitation. The waiver solicitation is scheduled to expire at 5:00 p.m., NYC time, on November 15.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on INVO:
- NAYA Biosciences and INVO Bioscience Announce Appointment of Dr. Peter Kash, Ed.D., MBA as Vice Chairman Following Closing of Their Pending Merger
- Free Registration Is Now Open For Tribe Public’s CEO and Q&A Presentation Webinar Event “Accelerating Biotech Value Creation” Featuring NAYA Biosciences CEO Dr. Daniel Teper On Tuesday, October 31, 2023
- INVO Bioscience cut to Hold at Maxim after NAYA Biosciences merger
- INVO Bioscience downgraded to Hold from Buy at Maxim
- INVO Bioscience and NAYA Biosciences Announce Definitive Merger Agreement To Establish Expanded Publicly Traded Life Science Company
